jnj
JNJ154.220USD
-1.439-0.93%
종가 05/09, 16:00（ET）시세는 15분 지연됩니다
371.00B시가총액
26.38P/E TTM
자세한 내용은 Johnson & Johnson 회사
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. The Company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolism. Medicines in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, cardiovascular, and vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eyecare professionals, and clinics.
회사 정보
회사 코드JNJ
회사 이름Johnson & Johnson
상장일Sep 25, 1944
설립일1887
CEOMr. Joaquin Boix Duato
직원 수138100
유형Ordinary Share
회계 연도 종료Sep 25
주소One Johnson & Johnson Plaza
도시NEW BRUNSWICK
증권 거래소NYSE Consolidated
국가United States of America
우편 번호08933
전화17325242455
웹사이트https://www.jnj.com/
회사 코드JNJ
상장일Sep 25, 1944
설립일1887
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
276.91K
-32.09%
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
178.01K
+14.96%
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
94.62K
+14.54%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
84.95K
+4.05K%
Prof. Dr. John C. Reed, M.D., Ph.D.
Prof. Dr. John C. Reed, M.D., Ph.D.
Executive Vice President - Innovative Medicine, Research and Development
Executive Vice President - Innovative Medicine, Research and Development
29.80K
+91.71%
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.59K
+18.96%
Ms. Kristen Mulholland
Ms. Kristen Mulholland
Chief Human Resource Officer, Executive Vice President
Chief Human Resource Officer, Executive Vice President
14.12K
+20.79%
Ms. Elizabeth (Liz) Forminard
Ms. Elizabeth (Liz) Forminard
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
10.90K
+30.72%
Mrs. Anne M. Mulcahy
Mrs. Anne M. Mulcahy
Independent Director
Independent Director
8.41K
+3.87%
Mr. Hubert Joly
Mr. Hubert Joly
Independent Director
Independent Director
5.00K
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
276.91K
-32.09%
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
178.01K
+14.96%
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
94.62K
+14.54%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
84.95K
+4.05K%
Prof. Dr. John C. Reed, M.D., Ph.D.
Prof. Dr. John C. Reed, M.D., Ph.D.
Executive Vice President - Innovative Medicine, Research and Development
Executive Vice President - Innovative Medicine, Research and Development
29.80K
+91.71%
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.59K
+18.96%
수익 분석
통화: USD업데이트 시간: Sun, Apr 6
통화: USD업데이트 시간: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
사업별USD
이름
수익
비율
Oncology-DARZALEX
11.67B
13.14%
Immunology-STELARA
10.36B
11.67%
Interventional Solutions
7.71B
8.68%
Surgery-General
5.36B
6.03%
Surgery-Advanced
4.49B
5.05%
Other
49.24B
55.43%
지역별USD
이름
수익
비율
United States
50.30B
56.63%
International
38.52B
43.37%
Europe
20.21B
22.76%
Asia-Pacific, Africa
13.59B
15.30%
Western Hemisphere, excluding U.S.
4.71B
5.31%
사업별
지역별
사업별USD
이름
수익
비율
Oncology-DARZALEX
11.67B
13.14%
Immunology-STELARA
10.36B
11.67%
Interventional Solutions
7.71B
8.68%
Surgery-General
5.36B
6.03%
Surgery-Advanced
4.49B
5.05%
Other
49.24B
55.43%
주주
업데이트 시간: Fri, Apr 4
업데이트 시간: Fri, Apr 4
주주 통계
유형
주주 통계
주주
비율
The Vanguard Group, Inc.
9.68%
State Street Global Advisors (US)
5.59%
BlackRock Institutional Trust Company, N.A.
5.37%
Geode Capital Management, L.L.C.
2.40%
State Farm Insurance Companies
1.32%
Other
75.65%
주주 통계
주주
비율
The Vanguard Group, Inc.
9.68%
State Street Global Advisors (US)
5.59%
BlackRock Institutional Trust Company, N.A.
5.37%
Geode Capital Management, L.L.C.
2.40%
State Farm Insurance Companies
1.32%
Other
75.65%
유형
주주
비율
Investment Advisor/Hedge Fund
33.54%
Investment Advisor
29.00%
Research Firm
2.97%
Pension Fund
2.28%
Bank and Trust
2.14%
Insurance Company
1.52%
Sovereign Wealth Fund
1.37%
Hedge Fund
0.75%
Foundation
0.10%
Other
26.34%
기관 주식 보유
업데이트 시간: Thu, Feb 20
업데이트 시간: Thu, Feb 20
보고 기간
기관 수
보유 주식
비율
변동
2025Q1
5936
1.78B
74.10%
-2.10K
2024Q4
5953
1.78B
74.14%
+8.28M
2024Q3
5699
1.77B
73.47%
+2.69M
2024Q2
5691
1.75B
72.75%
+9.12M
2024Q1
5685
1.73B
71.58%
-6.08M
2023Q4
5686
1.72B
71.40%
-7.80M
2023Q3
5524
1.72B
71.21%
-159.24M
2023Q2
5528
1.87B
71.81%
+6.27M
2023Q1
5490
1.85B
71.21%
-28.44M
2022Q4
5447
1.87B
71.55%
+6.54M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
The Vanguard Group, Inc.
231.82M
9.62%
+1.80M
+0.78%
Dec 31, 2024
State Street Global Advisors (US)
134.46M
5.58%
+210.35K
+0.16%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
130.00M
5.39%
+2.12M
+1.65%
Dec 31, 2024
Geode Capital Management, L.L.C.
57.67M
2.39%
+1.56M
+2.78%
Dec 31, 2024
State Farm Insurance Companies
31.68M
1.31%
--
--
Dec 31, 2024
Norges Bank Investment Management (NBIM)
30.36M
1.26%
+1.26M
+4.34%
Dec 31, 2024
Wellington Management Company, LLP
24.36M
1.01%
+431.20K
+1.80%
Dec 31, 2024
JP Morgan Asset Management
24.04M
1%
+5.40M
+29.00%
Dec 31, 2024
Morgan Stanley Smith Barney LLC
22.91M
0.95%
-654.88K
-2.78%
Dec 31, 2024
BlackRock Asset Management Ireland Limited
19.88M
0.82%
+587.38K
+3.05%
Dec 31, 2024
더 보기
관련 ETF
업데이트 시간: Tue, May 6
업데이트 시간: Tue, May 6
이름
비율
iShares U.S. Pharmaceuticals ETF
21.89%
FT Vest DJIA Dogs 10 Target Income ETF
13.93%
First Trust NASDAQ Pharmaceuticals ETF
8.21%
Proshares Ultra Health Care
7.49%
Health Care Select Sector SPDR Fund
7.35%
iShares U.S. Healthcare ETF
7.23%
American Century Focused Large Cap Value ETF
7.09%
VanEck Pharmaceutical ETF
6.95%
Fidelity MSCI Health Care Index ETF
6.31%
Touchstone Strategic Income ETF
6.07%
더 보기
iShares U.S. Pharmaceuticals ETF
비율21.89%
FT Vest DJIA Dogs 10 Target Income ETF
비율13.93%
First Trust NASDAQ Pharmaceuticals ETF
비율8.21%
Proshares Ultra Health Care
비율7.49%
Health Care Select Sector SPDR Fund
비율7.35%
iShares U.S. Healthcare ETF
비율7.23%
American Century Focused Large Cap Value ETF
비율7.09%
VanEck Pharmaceutical ETF
비율6.95%
Fidelity MSCI Health Care Index ETF
비율6.31%
Touchstone Strategic Income ETF
비율6.07%
주식 배당금
지난 5년 동안 총
56.79B
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
Jan 02, 2025
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Mar 04, 2025 going ex on Feb 18, 2025
Feb 18, 2025
Mar 04, 2025
Feb 18, 2025
Oct 15, 2024
JNJ.NB Final Cash Dividend of gross USD 1.24 paid on Dec 10, 2024 going ex on Nov 26, 2024
Nov 26, 2024
Dec 10, 2024
Nov 26, 2024
Jul 17, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Sep 10, 2024 going ex on Aug 27, 2024
Aug 27, 2024
Sep 10, 2024
Aug 27, 2024
Apr 16, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Jun 04, 2024 going ex on May 20, 2024
May 21, 2024
Jun 04, 2024
May 20, 2024
Jan 02, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Mar 05, 2024 going ex on Feb 16, 2024
Feb 20, 2024
Mar 05, 2024
Feb 16, 2024
Oct 19, 2023
JNJ.NB Final Cash Dividend of gross USD 1.19 paid on Dec 05, 2023 going ex on Nov 20, 2023
Nov 21, 2023
Dec 05, 2023
Nov 20, 2023
Jul 20, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Sep 07, 2023 going ex on Aug 25, 2023
Aug 28, 2023
Sep 07, 2023
Aug 25, 2023
Apr 18, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Jun 06, 2023 going ex on May 22, 2023
May 23, 2023
Jun 06, 2023
May 22, 2023
Jan 03, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 07, 2023 going ex on Feb 17, 2023
Feb 21, 2023
Mar 07, 2023
Feb 17, 2023
Oct 18, 2022
JNJ.NB Final Cash Dividend of gross USD 1.13 paid on Dec 06, 2022 going ex on Nov 21, 2022
Nov 22, 2022
Dec 06, 2022
Nov 21, 2022
더 보기
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음